BioAtla: A Buried ADC Concern Gets Some New Life In 2024 [Seeking Alpha]
BioAtla, Inc. (BCAB)
Company Research
Source: Seeking Alpha
Their approach is an attempt to harness the Warburg effect to conditionally activate immunological molecules. BioAtla has promising pipeline candidates, including mecbotamab vedotin, ozuriftamab vedotin, and evalstotug, with ongoing clinical studies. The BioAtla cash burn rate is high, currently taking the company into early 2025 at best. Topline Summary BioAtla NASDAQ: BCAB ) is a microcap biotech company focused on developing conditionally activated biologics for use in cancer therapy. In this case, rather than using some kind of cleavable mask, BCAB's platform relies on activating antibodies Recommended For You Recommended For You About BCAB Stock Related Stocks Trending Analysis Trending News
Show less
Read more
Impact Snapshot
Event Time:
BCAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BCAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BCAB alerts
High impacting BioAtla, Inc. news events
Weekly update
A roundup of the hottest topics
BCAB
News
- BioAtla, Inc. (NASDAQ: BCAB) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $7.00 price target on the stock.MarketBeat
- BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent Progress [Yahoo! Finance]Yahoo! Finance
- BioAtla Reports First Quarter 2024 Financial Results and Highlights Recent ProgressGlobeNewswire
- BioAtla to Participate in the Citizens JMP Life Sciences ConferenceGlobeNewswire
- BioAtla to Announce First Quarter 2024 Financial Results and Provide Business Highlights on May 14, 2024GlobeNewswire
BCAB
Earnings
- 5/14/24 - Beat
BCAB
Sec Filings
- 5/14/24 - Form 10-Q
- 5/14/24 - Form 8-K
- 5/1/24 - Form 4
- BCAB's page on the SEC website